

startupticker.ch

the swiss startup news channel

**S·E·C·A** Swiss Private Equity & Corporate Finance Association  
Schweizerische Vereinigung für Unternehmensfinanzierung  
Association Suisse des Investisseurs en Capital et de Financement

# Swiss Venture Capital Report 2013

Stefan Kyora, Thomas Heimann

Lucerne, February 2014

---

Partners/Sponsors startupticker.ch



Schweizerische Eidgenossenschaft  
Confédération suisse  
Confederazione Svizzera  
Confederaziun svizra

Swiss Confederation

Commission for Technology and Innovation CTI



W.A. DE VIGIER FOUNDATION



swisscom

— GEBERT RÜF STIFTUNG —  
WISSENSCHAFTL. BEWEGEN



CTI Invest The Swiss Venture Platform

## Preface by the Chairman

Dear reader

I am happy to present the second Swiss Venture Capital Report – a comprehensive analysis of venture capital investment in Swiss start-ups in 2013.

This second edition is a joint effort from the news portal startupticker.ch and the Swiss Private Equity & Corporate Finance Association (SECA).

First, I would like to thank Stefan Kyora and Thomas Heimann for the time and energy they have put into this interesting report, which is full of insights and surprising facts.

In addition, I would also like to thank all those who sent us their news, which we were able to share on our ecosystem.

I wish you an enlightening read.

Best regards

Jean-Pierre Vuilleumier

Chairman of startupticker.ch

## Key findings

We identified 90 rounds of venture capital financing in Switzerland in 2013. According to figures published by the participants, companies received a total of CHF415.3 million. The comparison with the previous year is very positive: the number of financed companies increased by almost 50% and the invested funds increased by more than 30%. In 2012, a total of 61 start-ups announced investment of CHF 316 million.

It is gratifying that much of the increase in financing rounds is attributable to early-stage and seed funding. The number of financing rounds in the early phase increased by 50%, growing from 30 to 45, and the funding volume almost tripled, rising from CHF32.5 million to CHF121.8 million (see page 6).

In addition, there was a significant increase in financing rounds of between CHF2 million and CHF10 million; the number doubled, rising from 15 in 2012 to a total of 30 transactions in 2013 (see page 8).

However, it should be noted that 2012 was a historically weak year for venture capital investments in terms of the number of financed companies as well as in terms of the overall invested amount. 2013

was not an exceptional good year for venture capital investments despite the clear improvement compared to 2012.

Life sciences start-ups saw the largest financing rounds. Basel-based Auris Medical, Covagen from Zurich and Lausanne-based Biocartis lead the list of the companies with the largest funding rounds. It is also noteworthy that several companies, including Geneva IT start-up Urturn, managed to generate large sums from well-known investors in the early stages or in the first round of financing (see page 4).

In general, the amounts invested per financing round in 2013 were quite low by international comparison. The median of funding overall in 2013 was CHF2.8 million (previous year: CHF1.9 million) – (see page 9).

The volume of investment measured by sector has biotech in front, followed by ICT and medtech on an almost equal footing. Based on the number of financing rounds, the ICT sector stands top with 30 investments, but the cleantech and consumer products segments were also up significantly compared with 2012, although on a comparable lower level than the three leading sectors (see page 5).

The canton rankings remain the same for the number of investments as for the amount invested, with Zurich, Geneva and Vaud taking the first three places. It's interesting to note that of the cantons with significant start-up activities, Zurich is diversified by sector the most, while Basel (both parts) is focused almost exclusively on life sciences (see page 9).

Support programmes and prizes are central to the promotion of start-ups; they not only provide an important source of financing but are also an instrument for external validation of a product or a business model. A good example is the CTI Start-up Programme. In 2013, young companies with the CTI Start-up Label received more than CHF100 million (see page 12).

The report collected and analysed publicly announced financing rounds of Swiss start-ups. In both 2012 and 2013, the level of funding of about two thirds of total transactions was made known, and only those 60 (of a total of 90 in 2013) rounds of financing, where the volume is known, were considered in the evaluation of the sums invested. The unpublished third comprises mainly seed and early stage financing rounds, which consist of comparatively small amounts of the total sum invested and thus do not dilute the validity of the study (see page 13).

## The top financing rounds

The top 20 venture capital rounds in Switzerland in 2013 accumulated a total of CHF 340 million (previous year: CHF 300 million), 82% (previous year: 95%) of the total investment volume. In both years, almost half was accounted for by the top five rounds. The life sciences start-ups lead the rankings: Auris Medical (biotech), Covagen (biotech) and Biocartis (medtech).

### Well-known investors

The investments in Covagen (biotech) of CHF 42 million, Obseva (biotech) with CHF 32 million and Urturn (ICT) with CHF 13 million, which are all in either an early development phase or in a first round of financing, from a surprisingly high number of well-known, almost exclusively foreign investors is remarkable. It's also interesting that many of these young companies have their operational headquarters in Switzerland.

Company	Sector	Phase	Canton	Figures (CHF m)
<b>Auris Medical</b>	biotech	later stage	BS	47.1
<b>Covagen</b>	biotech	later stage	ZH	42
<b>Biocartis</b>	medtech	later stage	VD	36.9
<b>Obseva</b>	biotech	early Stage	GE	32
<b>Cequr</b>	medtech	later stage	LU	25.2
<b>Finox</b>	biotech	later stage	BE	22
<b>Oncoethix</b>	biotech	later stage	VD	18
<b>Coresystems</b>	ICT	later stage	AG	14
<b>Urturn</b>	ICT	early stage	VD	13
<b>GetYourGuide</b>	ICT	later stage	ZH	12.9
<b>Numbrs</b>	ICT	early stage	ZH	11
<b>Wisekey</b>	ICT	later stage	GE	9.4
<b>Balluun</b>	ICT	later stage	ZH	8.1
<b>Sensimed</b>	medtech	later stage	VD	8
<b>Mind-NRG</b>	biotech	later stage	GE	7.4
<b>Delenex Therapeutics</b>	biotech	early stage	ZH	7.3
<b>Aquarius Water Holding</b>	cleantech	early stage	ZG	7.1
<b>TVP Solar</b>	cleantech	later stage	GE	6.6
<b>Telormedix</b>	biotech	later stage	TI	6
<b>ROMO Wind</b>	cleantech	later stage	ZG	5.9


## Sectors: life sciences lead

The life sciences sector (**biotech** and **medtech**) absorbed the most capital in 2013 with CHF276 million, up 54% on 2012, and 67% of total financing (previous year: CHF 179 million or 57%). Within life sciences, biotech (eg, Auris Medical, Covagen, Obseva) took CHF 185 million, or 45% of the total investment (previous year: CHF 66 million and 21%), clearly ahead of medtech, which took CHF91 million or 22% (previous year: CHF 113 million and 36%).

In second place is the **ICT** sector (with companies such as Coresystems, Urtun, GetYourGuide), with CHF92 million (down 26% on 2012) and 22% of the overall invested amount. In 2012, ICT was represented by CHF124 million, or 39% of the total financing amount. This decrease is due to some large transactions in 2012 that were missing in 2013.

**Cleantech** increased sharply in 2013. The sector recorded CHF30 million or 7% of the total amount of capital, up from only CHF2 million a year in 2012. As part of the ICT sector already shows, non IP-based (patents) and less capital-intensive areas are increasingly attracting venture capital. An example is the **consumer products** sector, which in 2013 achieved investment of CHF10 million, up from CHF3 million a year earlier.


Invested capital by sector (CHF m)



### Numerous ICT funding rounds

The **ICT** sector is ahead by number of transactions. It accounted for 30 financing rounds, or 33% of the total number of transactions (2012: 41%), ahead of **medtech** with 17 financing rounds, 19%, (2012: 20%) and **biotech** with 15 rounds, 17% (previous year: 15%). The **cleantech** sector is on 10 transactions (11%, previous year: 7%). The reason for the differences between the number and the total amount invested is the difference in the average level of funding rounds in each sector.

**Number of financing rounds by sector**




**Phases: early-stage growth**


We identified 15 seed, 45 early-stage and 30 later-stage financing rounds in 2013. Overall, CHF290.9 million flowed into later-stage financing, CHF121.8 million into early stage and CHF2.6 million into seed rounds.

It's gratifying that **early-stage financing** in particular rose sharply compared with last year. In 2012, this phase had 30 rounds of financing with the total volume of disclosed funding at CHF32.5 million. In 2013, this phase saw 45 rounds of financing (up 50%) with a total volume of CHF121.8 million (up 274%).

**Financing rounds by phase (number)**



**Invested capital by phase (CHF m)**



**Later-stage financing for life sciences and cleantech**

In 2013, late financing rounds (later stage) were made mainly in the life sciences area, with comparatively much higher sums available. In the ICT sector, financing rounds of late, but larger rounds were significantly smaller than in 2012. In 2013, the largest financing round totalled CHF53 million, while in 2012 the largest rounds achieved CHF107 million in total. However, in the cleantech sector investment resumed in the later rounds, while in 2012 it was restricted exclusively to the early phase and to a limited extent.


**Invested capital (CHF m) by round and sector (2013)**

	Seed	Early stage	Later stage	Total
<b>Biotech</b>		40.6	144.5	185.1
<b>Medtech</b>		17.2	74.1	91.3
<b>Healthcare/IT</b>	0.4	0.9		1.3
<b>Cleantech</b>		13.4	16.5	29.9
<b>Consumer products</b>	0.7	6.2	2.7	9.6
<b>Interdisciplinary</b>		6.6		6.6
<b>ICT</b>	1.5	36.9	53.1	91.5
<b>Micro/nano</b>				
<b>Total</b>	<b>2.6</b>	<b>121.8</b>	<b>290.9</b>	<b>415.3</b>


**More transactions between CHF2 million and CHF10 million**

The greater transaction volume in 2013 was due not only to more equity in the largest financing rounds (more than CHF10 million), but also because more money between CHF2 million to CHF10 million per financing round was available. Historically, capital in this area has often not been available to a sufficient extent. In 2012, 15 financing rounds of between CHF2 million and CHF10 million took place, compared with 30 rounds in 2013 (up 100%).

**Distribution of funding 2013**



**Distribution of funding 2012**





### Low funding rounds


The sums invested in most cases per financing round remain relatively low. Overall, in 2013 a median CHF2.8 million (previous year: CHF1.9 million) was invested per round.

The median early-stage financing in 2013 was CHF2 million (previous year: CHF1.5 million). The median of the later-stage rounds in 2013 was CHF7.7 million (previous year: CHF7.4 million). In 2013, the average in both cases is significantly higher (early stage: CHF3.9 million, previous year: CHF1.9 million; later stage: CHF13.2 million, previous year: CHF12.9). This suggests that by Swiss standards some high flyers succeed in generating large sums, while the bulk of financing rounds remain small by international comparison.

### Cantons: Zürich ahead


The breakdown of the number of financing rounds by canton offers no big surprises. Zurich is clearly in the lead (35 rounds, 39%) in front of Vaud (18, 20%), Geneva (9, 10%) and Basel (6, 7%). German-speaking Switzerland accounts for 64% compared with 34% in western Switzerland, with just one round of financing concerning Ticino. The wide distribution of start-ups over almost the whole of Switzerland is remarkable: in our list, financing rounds cover 16 cantons.

Number of financing rounds by canton



The picture changes somewhat if one considers the sums invested in each canton. The order remains approximately the same, but the margins change. In the canton of Zurich, a total of CHF 114.2 million (27%) is followed by Vaud (CHF89.7 million, 22%), Geneva (CHF64.8 million, 16%), Basel-Stadt (CHF48.6 million, 12%), Lucerne (CHF25.2 million, 6%) and Bern (CHF24 million, 6%). German-speaking Switzerland accounts for a total of CHF249.1 million (60%), compared with CHF160.2 million (39%) in western Switzerland.


**Invested sum by canton**



**Cantons: life sciences concentration in Basel**

The breakdown of the number of financing rounds by canton and sector shows that the cantons with the most activities in the start-up area, particularly Basel-Land and Basel-Stadt, are strongly focused on the life sciences sector. Although Vaud and Geneva also have a strong life sciences bias, other sectors such as ICT, micro/nano and consumer products are also present. The canton of Zurich is the most diversified by number of financing rounds, where all important sectors were the recipients of venture capital. The canton of Zug (cleantech 3 and ICT 1) is represented on the list probably for tax reasons.


**Shares of financing rounds by canton and sector**



**Sums invested by canton and sector**

A less diversified picture emerges when considering the amounts invested in each canton and sector. In those cantons with a strong life sciences presence – Basel, Geneva and Vaud – the importance of the sector as measured by the share of total investment rises significantly compared with the share of financing rounds. The other sectors in these cantons receive a relatively modest share. In numbers, this means, for example, that in Basel-Stadt, Basel-Land and Vaud, the proportion of life sciences measured by the total number of financing rounds is 50% to 60%, but this proportion rises to 80% to 100% based on the amount of capital invested. In Geneva, the proportion increases from 22% to 61%, demonstrating that much more capital flows into the life sciences sector. Although the sum invested in life sciences in the canton of Zurich accounts for more than 50% (a 26% share by number of financing rounds), diversification is greater compared with other cantons. Overall, across all cantons, the proportion of life sciences rises from 36% when measured by the number of financing rounds to 67%, based on the level of funds invested per sector.

Investment share by canton and sector



**Support: funded companies attract investors**

This year we analysed for the first time whether the start-ups in four selected support programmes attracted investment: recognition with the CTI Start-up Label, presentation at financing platform CTI Invest, and support through the WA de Vigier Foundation and venture kick.

Of the 90 start-ups funded in the past year, 29 have the CTI Start-up Label, a share of 32%. Overall, donors invested more than CHF100 million in these 29 companies. Of the 90, 32 presented at CTI Invest, with recorded investment to the tune of CHF100.4 million.

11 companies on our list are winners of the WA de Vigier Foundation’s Young Entrepreneur prize. These 11 companies have received total investment of CHF33.8 million. From the venture kick initiative, 14 of 90 start-up companies were supported and publicly announced investments of more than CHF14 million. Only a few of these supported start-ups announced the invested amount. The amount accrued by these companies is clearly higher.

## Methodology

The numbers are based on financing round reports by [startupticker.ch](http://startupticker.ch) and supplemented through other sources. Below, you will find the data of these financing rounds with links to the reports. Of course, this means that only investments that have been made public or were communicated in another way are included; in reality, the number of investments is higher. However, since the volume is not known, particularly for smaller financing rounds in the seed and early-stage phases, the results are not affected to a large degree.

The report focuses exclusively on venture capital investment. In addition, in the past year 10 investments in Swiss start-ups were made by strategic partners. Since these investments usually have the character of a partial exit, they have not been taken into account in our analysis; however, they are listed in a separate table at the end of the report. Private equity investment have not been considered.

We did not make any distinction between strategic and venture capital investment in the Venture Capital Report 2012, and a few private equity investments were also considered. To ensure the comparability of the figures, we have adjusted the 2012 report retrospectively.

The Investment phases are defined as follows:

- Seed: founders, 3Fs, foundations; average amount below CHF 1 million.
- Early stage: Round A, first round, BA and VCs; average amount between CHF1 million and CHF5 million.
- Later stage: growth, expansion, after Round A, VCs; average amount over CHF 5 million.

The following sectors were identified:

Biotech, medtech, healthcare IT, cleantech, consumer products, interdisciplinary, ICT, micro / nano.

## The authors

Stefan Kyora is a partner at Journalistenbüro Niedermann, Lucerne, and managing editor of [startupticker.ch](http://startupticker.ch). [stefan.kyora@jnb.ch](mailto:stefan.kyora@jnb.ch)

Thomas Heimann is responsible for research and statistics at SECA. [thomas.heimann@seca.ch](mailto:thomas.heimann@seca.ch)

## **About startupticker.ch**

www.startupticker.ch is an independent news platform for the Swiss start-up scene. We report in three languages on ambitious young companies from all industries and from all over Switzerland. In addition, we publish the latest information on funding opportunities, competitions and investors, complemented by the best start-up event calendar in Switzerland. Startupticker is operated by a non-profit association, and its partners and sponsors include the federal Commission for Technology and Innovation CTI, CTI Invest, W.A de Vigier Foundation, Gebert Rűf Foundation, Swisscom, SECA and other support organisations and companies. Thank you for your support.

## **About the Swiss Private Equity & Corporate Finance Association (SECA)**

The Swiss Private Equity & Corporate Finance Association (SECA) is the representative body for Switzerland's private equity, venture capital and corporate finance industries. SECA has the objective to promote private equity and corporate finance activities in Switzerland.

Members of the SECA include equity investment companies, banks, corporate finance advisors, auditing companies, management consultants, lawyers and private investors.

Venture Capital Financing Rounds in Switzerland 2013

Company	Industry	Figures (CHF m)	Phase	Investors	Canton	Support: CTI Start-up Label (C), Presentation at CTI Invest (I), Venture Kick (V), W.A. de Vigier (D).	Link / Source
<b>AEON Scientific</b>	Medtech	4	Later Stage	ZKB, private investors	ZH	C, I, V	<a href="http://www.startupticker.ch/en/news/june-2013/aeon-scientific-raises-chf4-million-in-series-b-financing-round">http://www.startupticker.ch/en/news/june-2013/aeon-scientific-raises-chf4-million-in-series-b-financing-round</a>
<b>Agile Wind Power</b>	Cleantech	n.a.	Early Stage	Hans Thomas Hug	ZH		<a href="http://www.startupticker.ch/en/news/july-2013/neuer-key-investor-fuer-agile-wind-power">http://www.startupticker.ch/en/news/july-2013/neuer-key-investor-fuer-agile-wind-power</a>
<b>Aquarius Water Holding</b>	Cleantech	7.1	Early Stage	Wermuth Assett Management	ZG		<a href="http://www.wermutham.com/media/press-releases.aspx#2013">http://www.wermutham.com/media/press-releases.aspx#2013</a>
<b>Arktis Radiation Detectors</b>	Interdis.	2.6	Early Stage	n.a.	ZH	C, I, D	<a href="http://www.startupticker.ch/en/news/october-2013/arktis-closes-usd-2-9million-financing-round">http://www.startupticker.ch/en/news/october-2013/arktis-closes-usd-2-9million-financing-round</a>
<b>Arviem</b>	IT	1.3	Early Stage	Investiere, ZKB, Swisscom Ventures	ZG		<a href="http://www.startupticker.ch/en/news/december-2013/arviem-raises-chf-1-35-million-from-swisscom-ventures-zkb-and-investiere">http://www.startupticker.ch/en/news/december-2013/arviem-raises-chf-1-35-million-from-swisscom-ventures-zkb-and-investiere</a>
<b>Auris Medical</b>	Biotech	47.1	Later Stage	Sofinnova Ventures, Sofinnova Partners	BS		<a href="http://www.startupticker.ch/en/news/april-2013/chf-47-1-mn-for-ground-breaking-inner-ear-therapies">http://www.startupticker.ch/en/news/april-2013/chf-47-1-mn-for-ground-breaking-inner-ear-therapies</a>
<b>Avance Pay</b>	IT	2	Early Stage	n.a.	BE		<a href="http://www.startupticker.ch/en/news/november-2013/avance-pay-closes-financing-round-of-chf-2-million">http://www.startupticker.ch/en/news/november-2013/avance-pay-closes-financing-round-of-chf-2-million</a>

Swiss Venture Capital Report 2013

<b>AVK systems</b>	IT	2	Early Stage	n.a.	VD	C	<a href="http://www.startupticker.ch/en/news/january-2014/2013-was-a-good-year-for-avk-systems">http://www.startupticker.ch/en/news/january-2014/2013-was-a-good-year-for-avk-systems</a>
<b>Balluun</b>	IT	8.1	Later Stage	Finoris and others	ZH		<a href="http://www.startupticker.ch/en/news/august-2013/balluun-announces-usd8-7-million-series-b-financing">http://www.startupticker.ch/en/news/august-2013/balluun-announces-usd8-7-million-series-b-financing</a>
<b>Biocartis</b>	Medtech	36.9	Later Stage	RMM (Rudi Mariën), Debiopharm Diagnostics SA, PMV Tina Fund, Valiance, Johnson & Johnson Development Corporation, Philips, the Wellcome Trust, and others	VD		<a href="http://www.startupticker.ch/en/news/november-2013/biocartis-raises-eur-30-million-and-prepares-market-entry">http://www.startupticker.ch/en/news/november-2013/biocartis-raises-eur-30-million-and-prepares-market-entry</a>
<b>BioVersys</b>	Biotech	n.a.	Early Stage	Private investors	BS	C, I, V	<a href="http://www.startupticker.ch/en/news/june-2013/bioversys-ag-closes-oversubscribed-series-a-financing-round">http://www.startupticker.ch/en/news/june-2013/bioversys-ag-closes-oversubscribed-series-a-financing-round</a>
<b>Bluetector</b>	Cleantech	n.a.	Seed	ZKB and private investors	LU	I	<a href="http://www.startupticker.ch/en/news/july-2013/bluetector-closes-seed-investment-round">http://www.startupticker.ch/en/news/july-2013/bluetector-closes-seed-investment-round</a>
<b>BPA Solutions</b>	IT	n.a.	Later Stage	Debiopharm Investment	VD		<a href="http://www.startupticker.ch/en/news/december-2013/bpa-solutions-closes-financing-round-with-debiopharm-investment">http://www.startupticker.ch/en/news/december-2013/bpa-solutions-closes-financing-round-with-debiopharm-investment</a>
<b>Buddybroker</b>	IT	0.6	Seed	Private investors	ZH	V	<a href="http://www.startupticker.ch/en/news/october-2013/finanzspritze-fu-r-buddybroker">http://www.startupticker.ch/en/news/october-2013/finanzspritze-fu-r-buddybroker</a>
<b>BugBuster</b>	IT	1	Early Stage	Polytech Ventures, Hasler Foundation and Private Investors from Business Angels Switzerland, Go Beyond	VD	V	<a href="http://www.startupticker.ch/en/news/november-2013/bugbuster-closes-chf-1million-series-a-round">http://www.startupticker.ch/en/news/november-2013/bugbuster-closes-chf-1million-series-a-round</a>
<b>Cegur</b>	Medtech	25.2	Later Stage	n.a.	LU		<a href="http://www.startupticker.ch/en/news/september-2013/cegur-closes-27-million-series-b-financing">http://www.startupticker.ch/en/news/september-2013/cegur-closes-27-million-series-b-financing</a>



Swiss Venture Capital Report 2013

<b>Chemspeed</b>	Interdis.	n.a.	Later Stage	Investnet	BL		<a href="http://www.startupticker.ch/en/news/august-2013/investnet-ag-provides-growth-capital-for-chemspeed">http://www.startupticker.ch/en/news/august-2013/investnet-ag-provides-growth-capital-for-chemspeed</a>
<b>Compliant Concept</b>	Medtech	n.a.	Early Stage	Debiopharm Invest, ZKB, EMPA	ZH	C, I, D, V	<a href="http://www.startupticker.ch/en/news/january-2013/compliant-concept-financing-round-and-success-in-t">http://www.startupticker.ch/en/news/january-2013/compliant-concept-financing-round-and-success-in-t</a>
<b>Coresystems</b>	IT	14	Later Stage	Private investors	AG		<a href="http://www.startupticker.ch/en/news/november-2013/coresystems-schliesst-serie-a-finanzierungsrunde-ueber-14-millionen-schweizer-franken-ab">http://www.startupticker.ch/en/news/november-2013/coresystems-schliesst-serie-a-finanzierungsrunde-ueber-14-millionen-schweizer-franken-ab</a>
<b>Covagen</b>	Biotech	42	Later Stage	Gimv, Ascent Biomedical Ventures, Novartis Venture Fund, Edmond de Rothschild Investment Partners, Seroba Kernel Life Sciences, Ventech and MP Healthcare Venture Management, Inc. and others	ZH	C, I	<a href="http://www.startupticker.ch/en/news/december-2013/covagen-secures-chf-42-million-in-series-b-financing">http://www.startupticker.ch/en/news/december-2013/covagen-secures-chf-42-million-in-series-b-financing</a>
<b>Credentis</b>	Medtech	1.6	Early Stage	ZKB, AKB, StartAngels Network, BioBAC Angels, private investors	AG	I	<a href="http://www.startupticker.ch/en/news/march-2013/credentis-ag-announces-successful-closing-of-b-rou">http://www.startupticker.ch/en/news/march-2013/credentis-ag-announces-successful-closing-of-b-rou</a>
<b>Creoptix</b>	Interdis.	3	Early Stage	ZKB, AKB, StartAngels Network, private investors	ZH	C, I	<a href="http://www.startupticker.ch/en/news/november-2013/creoptix-ag-closes-chf-3-million-series-a-financing">http://www.startupticker.ch/en/news/november-2013/creoptix-ag-closes-chf-3-million-series-a-financing</a>
<b>Dahu Sports Company</b>	Consumer Products	1	Early Stage	Network of investiere and Business Angels Suisse Romande, Capital Risque Fribourg and Effort Fribourg	FR	C	<a href="http://www.startupticker.ch/en/news/july-2013/dahu-raises-approximately-chf-1-million">http://www.startupticker.ch/en/news/july-2013/dahu-raises-approximately-chf-1-million</a>
<b>Delenex Therapeutics</b>	Biotech	7.3	Early Stage	HBM Ventures, Novo A/S, SV Life Sciences, BioMedinvest, Venture Incubator and others	ZH		<a href="http://www.startupticker.ch/en/news/november-2013/delenex-therapeutics-closes-chf-7-3-million-series-a3-financing">http://www.startupticker.ch/en/news/november-2013/delenex-therapeutics-closes-chf-7-3-million-series-a3-financing</a>
<b>Diagnoplex</b>	Biotech	1.3	Early Stage	Debiopharm Investment, Neomed, Initiative Capital Romandie and others	VD	C, I	<a href="http://www.startupticker.ch/en/news/june-2013/diagnoplex-closes-a-financing-round-led-by-debiopharm-group">http://www.startupticker.ch/en/news/june-2013/diagnoplex-closes-a-financing-round-led-by-debiopharm-group</a>

Swiss Venture Capital Report 2013

<b>Diamond Heels</b>	Consumer Products	n.a.	Seed	Incuray	ZH		<a href="http://www.startupticker.ch/en/news/december-2013/incuray-steigt-bei-diamond-heels-ein">http://www.startupticker.ch/en/news/december-2013/incuray-steigt-bei-diamond-heels-ein</a>
<b>Distalmotion</b>	Medtech	n.a.	Early Stage	Zühlke Ventures, BlueOcean Ventures and private investors	VD	V	<a href="http://www.startupticker.ch/en/news/august-2013/distalmotion-closes-series-a-financing-round">http://www.startupticker.ch/en/news/august-2013/distalmotion-closes-series-a-financing-round</a>
<b>DomoSafety</b>	Healthcare / IT	0.9	Early Stage	Networks of Business Angels Suisse Romande, investiere, A3 Angels club, GoBeyond and other private investors	VD	I	<a href="http://www.startupticker.ch/en/news/july-2013/domosafety-closes-second-financing-round-for-chf-935-000">http://www.startupticker.ch/en/news/july-2013/domosafety-closes-second-financing-round-for-chf-935-000</a>
<b>Dualsystems Biotech</b>	Biotech	n.a.	Later Stage	n.a.	ZH	C	<a href="http://www.startupticker.ch/en/news/september-2013/dualsystems-biotech-closes-series-c-financing-round">http://www.startupticker.ch/en/news/september-2013/dualsystems-biotech-closes-series-c-financing-round</a>
<b>Dubois et fils</b>	Consumer Products	1.5	Early Stage	Private investors	BS		<a href="http://www.startupticker.ch/en/news/march-2013/chf1-5-million-successful-crowdfunding-by-dubois-e">http://www.startupticker.ch/en/news/march-2013/chf1-5-million-successful-crowdfunding-by-dubois-e</a>
<b>Endignorance</b>	IT	0.3	Seed	Private investors	GE		<a href="http://www.startupticker.ch/en/news/february-2013/social-enterprise-attracts-investors-and-facebook">http://www.startupticker.ch/en/news/february-2013/social-enterprise-attracts-investors-and-facebook</a>
<b>Faction</b>	Consumer Products	2.7	Later Stage	Octopus Investments, private investors	VS		<a href="http://www.startupticker.ch/en/news/october-2013/3-million-dollar-for-swiss-ski-manufactory">http://www.startupticker.ch/en/news/october-2013/3-million-dollar-for-swiss-ski-manufactory</a>
<b>Faveeo</b>	IT	0.3	Seed	Private investors	GE		<a href="http://www.startupticker.ch/en/news/october-2013/faveeo-raises-350k-in-seed-funding">http://www.startupticker.ch/en/news/october-2013/faveeo-raises-350k-in-seed-funding</a>
<b>Finox</b>	Biotech	22	Later Stage	BV Holding and others	BE		<a href="http://www.startupticker.ch/en/news/september-2013/22-millionen-franken-fuer-willy-michels-neues-start-up">http://www.startupticker.ch/en/news/september-2013/22-millionen-franken-fuer-willy-michels-neues-start-up</a>
<b>Flatev</b>	Consumer Products	0.7	Seed	n.a.	ZH	V	<a href="http://www.startupticker.ch/en/news/august-2013/flatev-s-financing-round-with-a-good-start">http://www.startupticker.ch/en/news/august-2013/flatev-s-financing-round-with-a-good-start</a>

Swiss Venture Capital Report 2013

<b>Flisom</b>	Cleantech	n.a.	Later Stage	Tata and others	ZH	C, I	<a href="http://www.startupticker.ch/en/news/february-2013/flisom-raises-substantially-large-investment">http://www.startupticker.ch/en/news/february-2013/flisom-raises-substantially-large-investment</a>
<b>Gene Signal</b>	Biotech	n.a.	Later Stage	Private investors	VD		<a href="http://www.startupticker.ch/en/news/march-2013/gene-signal-announces-completion-of-private-fundin">http://www.startupticker.ch/en/news/march-2013/gene-signal-announces-completion-of-private-fundin</a>
<b>GetYourGuide</b>	IT	12.9	Later Stage	Spark Capital, Highland Capital Partners Europe	ZH	C, I, D	<a href="http://www.startupticker.ch/en/news/january-2013/getyourguide-erhalt-eine-investition-von-14-millio">http://www.startupticker.ch/en/news/january-2013/getyourguide-erhalt-eine-investition-von-14-millio</a>
<b>Hocoma</b>	Medtech	n.a.	Later Stage	n.a.	ZH	C, I, D	<a href="http://www.startupticker.ch/en/news/july-2013/hocoma-growth-in-2012-and-closing-of-a-financing-round">http://www.startupticker.ch/en/news/july-2013/hocoma-growth-in-2012-and-closing-of-a-financing-round</a>
<b>ID Quantique</b>	IT	5.1	Later Stage	Qwave Capital	GE	C, I, D	<a href="http://www.startupticker.ch/en/news/october-2013/qwave-capital-invests-5-6-million-in-id-quantique">http://www.startupticker.ch/en/news/october-2013/qwave-capital-invests-5-6-million-in-id-quantique</a>
<b>iMusician Digital</b>	IT	n.a.	Early Stage	investiere, ZKB	ZH		<a href="http://www.startupticker.ch/en/news/june-2013/investiere-closes-1m-round-for-imusician">http://www.startupticker.ch/en/news/june-2013/investiere-closes-1m-round-for-imusician</a>
<b>Insphero</b>	Biotech	2	Later Stage	n.a.	ZH	C, I, D, V	<a href="http://www.startupticker.ch/en/news/june-2013/insphero-secures-chf-2-million-financing">http://www.startupticker.ch/en/news/june-2013/insphero-secures-chf-2-million-financing</a>
<b>Keylemon</b>	IT	n.a.	Early Stage	Debiopharm Investment, Swisscom Ventures and others	VS	V, I	<a href="http://www.startupticker.ch/en/news/september-2013/keylemon-secures-series-a-investment">http://www.startupticker.ch/en/news/september-2013/keylemon-secures-series-a-investment</a>
<b>Léman Micro Devices</b>	Medtech	n.a.	Early Stage	Zühlke, Start Angels Network	VD	C, I	<a href="http://www.startupticker.ch/en/news/july-2013/leman-micro-devices-closes-series-a-financing-round">http://www.startupticker.ch/en/news/july-2013/leman-micro-devices-closes-series-a-financing-round</a>
<b>Medical Insights</b>	Healthcare / IT	n.a.	Early Stage	Adrian Bult, Karl Landert and other private investors	BS		<a href="http://www.startupticker.ch/en/news/july-2013/seasoned-investors-support-medical-insights">http://www.startupticker.ch/en/news/july-2013/seasoned-investors-support-medical-insights</a>
<b>Mila</b>	IT	3	Early Stage	Private investors (Adrian Bult, Peter Zencke and others)	ZH		<a href="http://www.startupticker.ch/en/news/march-2013/mila-sichert-sich-finanzierung-von-3-millionen-fra">http://www.startupticker.ch/en/news/march-2013/mila-sichert-sich-finanzierung-von-3-millionen-fra</a>

*Swiss Venture Capital Report 2013*

<b>Mind-NRG</b>	Biotech	7.4	Later Stage	LRM and others	GE		<a href="http://www.startupticker.ch/en/news/september-2013/mind-nrg-completes-6-million-euro-series-b-financing">http://www.startupticker.ch/en/news/september-2013/mind-nrg-completes-6-million-euro-series-b-financing</a>
<b>Morewind</b>	Cleantech	1.1	Early Stage	Aravis	ZH		<a href="http://www.swissventureguide.ch/2013/Investor-Profiles/Aravis-SA">http://www.swissventureguide.ch/2013/Investor-Profiles/Aravis-SA</a>
<b>MySwiss-Chocolate</b>	IT	1.6	Later Stage	ZKB and others	ZH		<a href="http://www.startupticker.ch/en/news/december-2013/1-6-millionen-fuer-chocogreets-app">http://www.startupticker.ch/en/news/december-2013/1-6-millionen-fuer-chocogreets-app</a>
<b>Naviswiss</b>	Medtech	1	Early Stage	Investiere, private investors	BL	I	<a href="http://www.startupticker.ch/en/news/december-2013/naviswiss-secures-more-than-chf-1-million">http://www.startupticker.ch/en/news/december-2013/naviswiss-secures-more-than-chf-1-million</a>
<b>NBE Therapeutics</b>	Biotech	n.a.	Seed	Boehringer Ingelheim Venture Fund	BS		<a href="http://www.startupticker.ch/en/news/june-2013/successful-first-year-for-nbe-therapeutics">http://www.startupticker.ch/en/news/june-2013/successful-first-year-for-nbe-therapeutics</a>
<b>Netagenda</b>	IT	0.1	Seed	Crowdfunding via 7Crowd	ZH		<a href="http://www.startupticker.ch/en/news/november-2013/crowdfunding-kampagne-von-rightclearing-auf-gutem-weg">http://www.startupticker.ch/en/news/november-2013/crowdfunding-kampagne-von-rightclearing-auf-gutem-weg</a>
<b>Nexavis</b>	IT	n.a.	Early Stage	Private investor	GE		<a href="http://www.startupticker.ch/en/news/october-2013/nexavis-secures-new-investment-to-fuel-international-expansion">http://www.startupticker.ch/en/news/october-2013/nexavis-secures-new-investment-to-fuel-international-expansion</a>
<b>Nezasa</b>	IT	n.a.	Seed	Paul Sevinç, Myke Näef and others	ZH		<a href="http://www.startupticker.ch/en/news/august-2013/nezasa-closes-seed-investment-round">http://www.startupticker.ch/en/news/august-2013/nezasa-closes-seed-investment-round</a>
<b>Numbrs</b>	IT	11	Early Stage	Centralway	ZH		<a href="http://www.startupticker.ch/en/news/september-2013/schweizer-banking-startup-numbrs-erhaelt-weitere-3-8-millionen-von-centralway">http://www.startupticker.ch/en/news/september-2013/schweizer-banking-startup-numbrs-erhaelt-weitere-3-8-millionen-von-centralway</a>
<b>Obseva</b>	Biotech	32	Early Stage	Sofinnova Partners, Sofinnova Ventures, Novo A/S, MS Ventures and others	GE		<a href="http://www.startupticker.ch/en/news/august-2013/obseva-sa-announces-chf-32-million-funding">http://www.startupticker.ch/en/news/august-2013/obseva-sa-announces-chf-32-million-funding</a>

Swiss Venture Capital Report 2013

<b>Oncoethix</b>	Biotech	18	Later Stage	SV Life Sciences, Edmond de Rothschild Investment Partners, Index Ventures, Endeavour Vision and others	VD		<a href="http://www.startupticker.ch/en/news/july-2013/oncoethix-closes-18-million-chf-series-b-financing">http://www.startupticker.ch/en/news/july-2013/oncoethix-closes-18-million-chf-series-b-financing</a>
<b>OTI Greentech</b>	Cleantech	4	Later Stage	Green Gateway Fund	ZG		<a href="http://www.startupticker.ch/en/news/february-2013/oti-greentech-successfully-completes-expansion-fun">http://www.startupticker.ch/en/news/february-2013/oti-greentech-successfully-completes-expansion-fun</a>
<b>Piqur</b>	Biotech	n.a.	Seed	Private Investors	BS	C, V	<a href="http://www.startupticker.ch/en/news/september-2013/piqur-closed-third-seed-financing-round-and-received-eurostars-grant">http://www.startupticker.ch/en/news/september-2013/piqur-closed-third-seed-financing-round-and-received-eurostars-grant</a>
<b>preloved.ch</b>	IT	n.a.	Seed	Peter Schüpbach	BE		<a href="http://www.startupticker.ch/en/news/february-2013/second-hand-portal-mit-prominentem-business-angel">http://www.startupticker.ch/en/news/february-2013/second-hand-portal-mit-prominentem-business-angel</a>
<b>Qualysense</b>	Interdis.	1	Early Stage	Private investors	ZH	C, I, V	<a href="http://www.startupticker.ch/en/news/april-2013/qualysense-closes-third-financing-round">http://www.startupticker.ch/en/news/april-2013/qualysense-closes-third-financing-round</a>
<b>Qvanteq</b>	Medtech	4	Early Stage	Private Investors	ZH	C, I, V	<a href="http://www.startupticker.ch/en/news/february-2013/qvanteq-closes-series-b-financing-round-of-chf4-mi">http://www.startupticker.ch/en/news/february-2013/qvanteq-closes-series-b-financing-round-of-chf4-mi</a>
<b>Rayneer</b>	IT	2	Early Stage	ZKB, Wilma.com and private investors	ZH	C, I	<a href="http://www.startupticker.ch/en/news/october-2013/rayneer-tv-closes-chf-2million-financing-round">http://www.startupticker.ch/en/news/october-2013/rayneer-tv-closes-chf-2million-financing-round</a>
<b>Reha Technology AG</b>	Medtech	n.a.	Early Stage	HBM Partners	SO		<a href="http://www.startupticker.ch/en/news/january-2013/hbm-investiert-in-medtech-start-up-reha-technology">http://www.startupticker.ch/en/news/january-2013/hbm-investiert-in-medtech-start-up-reha-technology</a>
<b>Rightclearing</b>	IT	0.1	Early Stage	Crowdfunding via 7Crowd	ZH		<a href="http://www.startupticker.ch/en/news/january-2014/rightclearing-generiert-100-000-franken-per-crowdfunding">http://www.startupticker.ch/en/news/january-2014/rightclearing-generiert-100-000-franken-per-crowdfunding</a>
<b>ROMO Wind</b>	Cleantech	5.9	Later Stage	Yellow&Blue, ABB Technology Ventures, b-to-v	ZG		<a href="http://www.startupticker.ch/en/news/april-2013/swiss-based-romo-wind-raises-new-capital">http://www.startupticker.ch/en/news/april-2013/swiss-based-romo-wind-raises-new-capital</a>

Swiss Venture Capital Report 2013

<b>Sanovation</b>	Healthcare / IT	0.35	Seed	Private investors	ZH	I, D	<a href="http://www.startupticker.ch/en/news/november-2013/sanovation-ag-closes-financing-round-and-continues-its-battle-against-chronic-pain">http://www.startupticker.ch/en/news/november-2013/sanovation-ag-closes-financing-round-and-continues-its-battle-against-chronic-pain</a>
<b>Savelli</b>	Consumer Products	3.7	Early Stage	Innogest, Rho Ventures, private investors	GE		<a href="http://www.crunchbase.com/company/savelli">http://www.crunchbase.com/company/savelli</a>
<b>SAV-IOL</b>	Medtech	2	Early Stage	Aevis Holding	NE		<a href="http://www.startupticker.ch/en/news/march-2013/aevis-holding-sa-a-souscrit-une-participation-mino">http://www.startupticker.ch/en/news/march-2013/aevis-holding-sa-a-souscrit-une-participation-mino</a>
<b>Sensima Technology</b>	Micro/Nano	n.a.	Later Stage	Go Beyond Investor Network	VD	C, I	<a href="http://www.startupticker.ch/en/news/may-2013/first-closing-of-sensima-s-series-b-financing-round">http://www.startupticker.ch/en/news/may-2013/first-closing-of-sensima-s-series-b-financing-round</a>
<b>Sensimed</b>	Medtech	8	Later Stage	Vertex Venture	VD	C, I, D	<a href="http://www.startupticker.ch/en/news/july-2013/vertex-invests-chf-8million-in-sensimed">http://www.startupticker.ch/en/news/july-2013/vertex-invests-chf-8million-in-sensimed</a>
<b>Skiioo</b>	Consumer Products	n.a.	Early Stage	Debiopharm Investment	VD	I	<a href="http://www.startupticker.ch/en/news/september-2013/debiopharm-group-takes-a-stake-in-skiioo-a-start-up-based-in-vaud">http://www.startupticker.ch/en/news/september-2013/debiopharm-group-takes-a-stake-in-skiioo-a-start-up-based-in-vaud</a>
<b>Skyline Parking</b>	Interdis	n.a.	Later Stage	KMU Capital	ZH	C, I	<a href="http://www.startupticker.ch/en/news/july-2013/raiffeisen-beteiligt-sich-an-skyline-parking">http://www.startupticker.ch/en/news/july-2013/raiffeisen-beteiligt-sich-an-skyline-parking</a>
<b>Smallrivers</b>	IT	2	Later Stage	Debiopharm Investment, Polytech Ventures	VD		<a href="http://www.startupticker.ch/en/news/september-2013/debiopharm-investment-entre-dans-le-capital-de-la-smallrivers">http://www.startupticker.ch/en/news/september-2013/debiopharm-investment-entre-dans-le-capital-de-la-smallrivers</a>
<b>Sophia Genetics</b>	Medtech	3.8	Early Stage	n.a.	VD	C, I	<a href="http://www.startupticker.ch/en/news/december-2013/sophia-genetics-sa-invitee-au-10-downing-street">http://www.startupticker.ch/en/news/december-2013/sophia-genetics-sa-invitee-au-10-downing-street</a>
<b>Spinomix</b>	Medtech	2.8	Early Stage	Private Investors, Debiopharm Investment	VD	C, I, D	<a href="http://www.startupticker.ch/en/news/january-2013/spinomix-closes-a-usd3-million-financing-round-led">http://www.startupticker.ch/en/news/january-2013/spinomix-closes-a-usd3-million-financing-round-led</a>

Swiss Venture Capital Report 2013

<b>Squirro</b>	IT	n.a.	Early Stage	Private Investors, Hoepfner, ZKB, Hasler Foundation, Formula VC and other	ZH	C, I, D	<a href="http://www.startupticker.ch/en/news/may-2013/squirro-announces-new-product-and-funding">http://www.startupticker.ch/en/news/may-2013/squirro-announces-new-product-and-funding</a>
<b>SuitArt</b>	Consumer Products	n.a.	Seed	André Mäder	ZH		<a href="http://www.startupticker.ch/en/news/march-2013/starke-internationale-expansion-bei-suitart">http://www.startupticker.ch/en/news/march-2013/starke-internationale-expansion-bei-suitart</a>
<b>Swissto12</b>	Micro/Nano	n.a.	Seed	ZKB	VD	C, I, D, V	<a href="http://www.startupticker.ch/en/news/june-2013/zuercher-kantonalbank-invests-in-swissto12-sa">http://www.startupticker.ch/en/news/june-2013/zuercher-kantonalbank-invests-in-swissto12-sa</a>
<b>Swisstom</b>	Medtech	2	Early Stage	Zühlke Ventures and others	GR	C, I	<a href="http://www.startupticker.ch/en/news/january-2013/zweite-finanzierungsrunde-fur-swisstom">http://www.startupticker.ch/en/news/january-2013/zweite-finanzierungsrunde-fur-swisstom</a>
<b>Talentry</b>	IT	1.5	Early Stage	Russian Internet Technology Fund	ZH		<a href="http://www.startupticker.ch/en/news/december-2013/talentry-com-closes-us-1-7m-investment-round-with-ritf-fund-managed-by-black-river-ventures">http://www.startupticker.ch/en/news/december-2013/talentry-com-closes-us-1-7m-investment-round-with-ritf-fund-managed-by-black-river-ventures</a>
<b>Telormedix</b>	Biotech	6	Later Stage	Aravis Venture, Proquest Investments	TI		<a href="http://www.startupticker.ch/en/news/december-2013/telormedix-raises-chf-6-m-in-series-b-financing-round">http://www.startupticker.ch/en/news/december-2013/telormedix-raises-chf-6-m-in-series-b-financing-round</a>
<b>Tenon Technology</b>	Medtech	n.a.	Early Stage	Zühlke Ventures	ZH		<a href="http://www.startupticker.ch/en/news/march-2013/zuhlke-ventures-invests-in-medical-start-up-tenon">http://www.startupticker.ch/en/news/march-2013/zuhlke-ventures-invests-in-medical-start-up-tenon</a>
<b>Treksoft</b>	IT	n.a.	Early Stage	Redalpine, Innovationsstiftung der Schwyzer Kantonalbank, Armin Meyer, Adrian Locher and other private investors	BE	I	<a href="http://www.startupticker.ch/en/news/august-2013/hochkaraetige-business-insider-und-risikokapitalgeber-investieren-in-treksoft">http://www.startupticker.ch/en/news/august-2013/hochkaraetige-business-insider-und-risikokapitalgeber-investieren-in-treksoft</a>
<b>TVP Solar</b>	Cleantech	6.6	Later Stage	n.a.	GE		<a href="http://www.startupticker.ch/en/news/august-2013/tvp-solar-receives-chf-6-6-million-equity-injection">http://www.startupticker.ch/en/news/august-2013/tvp-solar-receives-chf-6-6-million-equity-injection</a>
<b>Urban Farmers</b>	Cleantech	0.7	Early Stage	n.a.	ZH	C, V	<a href="http://www.startupticker.ch/en/news/december-2013/urbanfarmers-closes-interim-investment-round">http://www.startupticker.ch/en/news/december-2013/urbanfarmers-closes-interim-investment-round</a>

**Swiss Venture Capital Report 2013**

<b>Urban Games</b>	IT	0.2	Seed	Crowdfunding via Gambitious	SH	<a href="http://www.startupticker.ch/en/news/march-2013/successful-crowdfunding-campaign-for-train-fever">http://www.startupticker.ch/en/news/march-2013/successful-crowdfunding-campaign-for-train-fever</a>
<b>Urturn</b>	IT	13	Early Stage	Debiopharm Investment, Balderton Capital	VD	<a href="http://www.startupticker.ch/en/news/may-2013/urturn-secures-usd13-4m-investment-led-by-balderton-capital">http://www.startupticker.ch/en/news/may-2013/urturn-secures-usd13-4m-investment-led-by-balderton-capital</a>
<b>Windward</b>	Cleantech	4.5	Early Stage	Aleph	ZH	<a href="http://www.globes.co.il/serveen/globes/docview.asp?did=1000891698">http://www.globes.co.il/serveen/globes/docview.asp?did=1000891698</a>
<b>Wisekey</b>	IT	9.4	Later Stage	Saudi Crown Investment	GE	<a href="http://www.startupticker.ch/en/news/september-2013/wisekey-raised-additional-10-million">http://www.startupticker.ch/en/news/september-2013/wisekey-raised-additional-10-million</a>

**Strategic investments in Switzerland in Swiss start-ups 2013**

Company	Industry	Figures (CHF m)	Phase	Investors	Canton	Support: CTI Start-up Label (C) or Venture Kick	Link /Source
<b>ADC Therapeutics</b>	Biotech	36.4	Later Stage	Medimmune, Auen Therapeutics	VD		<a href="http://www.startupticker.ch/en/news/october-2013/medimmune-and-auven-invest-usd-40-million-in-adc-therapeutics">http://www.startupticker.ch/en/news/october-2013/medimmune-and-auven-invest-usd-40-million-in-adc-therapeutics</a>
<b>Calypso Biotech</b>	Biotech	2.8	Early Stage	MS Ventures	GE		<a href="http://www.startupticker.ch/en/news/march-2013/sixth-merck-serono-spin-off-company-to-focus-on-ga">http://www.startupticker.ch/en/news/march-2013/sixth-merck-serono-spin-off-company-to-focus-on-ga</a>



*Swiss Venture Capital Report 2013*

<b>Chromacon</b>	Biotech	n.a.	Later Stage	JSR Corporation	ZH	C	<a href="http://www.startupticker.ch/en/news/february-2013/strategic-investor-for-chromacon">http://www.startupticker.ch/en/news/february-2013/strategic-investor-for-chromacon</a>
<b>Darwin Airline</b>	Interdis.	n.a.	Later Stage	Etihad Airways	TI		<a href="http://www.startupticker.ch/en/news/november-2013/etihad-takes-a-33-3-stake-in-young-swiss-carrier-darwin-airline">http://www.startupticker.ch/en/news/november-2013/etihad-takes-a-33-3-stake-in-young-swiss-carrier-darwin-airline</a>
<b>Endosense</b>	Medtech	4	Later Stage	Strategic investor	GE	C	<a href="http://www.startupticker.ch/en/news/march-2013/endosense-raises-additional-chf-4m">http://www.startupticker.ch/en/news/march-2013/endosense-raises-additional-chf-4m</a>
<b>Glasstoenergy</b>	Cleantech	n.a.	Early Stage	Groupe E, Capital Risque Fribourg, CPA Group	FR		<a href="http://www.startupticker.ch/en/news/may-2013/groupe-e-and-capital-risque-fribourg-invest-in-g2e">http://www.startupticker.ch/en/news/may-2013/groupe-e-and-capital-risque-fribourg-invest-in-g2e</a>
<b>Paradox Engineering</b>	Cleantech	n.a.	Later Stage	Minebea	TI		<a href="http://www.startupticker.ch/en/news/december-2013/japanese-corporation-minebea-takes-a-stake-in-paradox-engineering">http://www.startupticker.ch/en/news/december-2013/japanese-corporation-minebea-takes-a-stake-in-paradox-engineering</a>
<b>Silp</b>	IT	n.a.	Early Stage	x28	ZH		<a href="http://www.startupticker.ch/en/news/march-2013/strategische-partnerschaft-und-frisches-kapital-fu">http://www.startupticker.ch/en/news/march-2013/strategische-partnerschaft-und-frisches-kapital-fu</a>
<b>Watson</b>	IT	n.a.	Early Stage	AZ Medien, BT Holding	ZH		<a href="http://www.startupticker.ch/en/news/october-2013/wanner-finanziert-watson">http://www.startupticker.ch/en/news/october-2013/wanner-finanziert-watson</a>
<b>Wisekey</b>	IT	n.a.	Later Stage	Grupo Jaime Câmara (strategic investor)	GE		<a href="http://www.startupticker.ch/en/news/may-2013/wisekey-receives-strategic-investment-from-leading-brazilian-media-group">http://www.startupticker.ch/en/news/may-2013/wisekey-receives-strategic-investment-from-leading-brazilian-media-group</a>